Baxter International Inc. (NYSE: BAX) today announced the commercial launch of HYLENEX recombinant (hyaluronidase human injection) for use in pediatric rehydration at the 2009 American College of ...

SAN DIEGO, Aug. 31 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a ...

Company also lifted notice of breach on Baxter Healthcare, which is manufacturing the product. Halozyme Therapeutics says that it has identified a corrective action plan and regulatory strategy to ...

Baxter announced a voluntary recall of all lots of Hylenex recombinant (hyaluronidase human injection) as a precautionary measure due to instances of particulate matter observed in a limited number of ...

NEW YORK, May 17 (Reuters) - Baxter International Inc shares fell 3 percent on Monday after its partner Halozyme Therapeutics Inc voluntarily recalled certain lots of their fluid-absorption drug due ...

NEW YORK, May 16 (Reuters) - Biopharmaceutical company Halozyme Therapeutics Inc on Sunday said Baxter International Inc has had "manufacturing failures" in making Hylenex, a fluid absorption drug ...

DEERFIELD, Ill., May 17, 2010 (BUSINESS WIRE) -- Baxter International Inc. announced today that a voluntary recall of all manufactured lots of HYLENEX recombinant (hyaluronidase human injection) has ...

Agreement includes $10 million upfront and a $20-million equity investment. Halozyme Therapeutics and Baxter Healthcare expanded their existing Hylenex recombinant (hyaluronidase human injection) ...